Adjuvant Sintilimab with or without Anti-VEGF Therapy After Resection in Hepatocellular Carcinoma with Microvascular Invasion: A Multicenter Retrospective Study

Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Yi-Tao Zheng, Yun-Feng Shan, Shu-Qun Cheng · 2025

Read Adjuvant Sintilimab with or without Anti-VEGF Therapy After Resection in Hepatocellular Carcinoma with Microvascular Invasion: A Multicenter Retrospective Study by Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Yi-Tao Zheng, Yun-Feng Shan, Shu-Qun Cheng (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12717793.txt.

Description

Kang Wang and co-authors studied extra drug treatment after liver cancer surgery in two thousand twenty-five. Patients whose tumors invaded tiny vessels face high relapse risk after resection. The team asked whether an immune drug, alone or with a vessel-blocking drug, improves outcomes.

They reviewed one hundred seventy patients from three Chinese centers treated in two thousand twenty-two. Groups got observation, the immune drug sintilimab, or sintilimab plus anti-VEGF therapy. Relapse or death occurred in about sixty-one percent of the observation group, versus about forty-one percent in each drug group. Median relapse-free time nearly doubled with either drug plan. Added vessel therapy gave no clear extra gain, so it may not be needed for all.

Catalog record

CREATORKang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Yi-Tao Zheng, Yun-Feng Shan, Shu-Qun Cheng
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE25 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12717793

Browse the full library · About the Tower of Babel